Retail sales of prescription drugs will exceed $100 billion this year, according to the National Association of Chain Drug Stores. Ronald L. Ziegler, president and CEO of the association, made the history-making announcement at the 41st NACDS Pharmacy Conference & Managed Care Forum in San Diego in August.
Retail sales of prescription drugs will exceed $100 billion this year, according to the National Association of Chain Drug Stores. Ronald L. Ziegler, president and CEO of the association, made the history-making announcement at the 41st NACDS Pharmacy Conference & Managed Care Forum in San Diego in August.
By the end of 1998, Ziegler said, sales of prescription products will have reached $102.5 billion, an increase of more than 15% over last year. In 1997, sales reached $89 billion. That accounts for 2.8 billion dispensed prescriptions, which is an increase of 6% from the 2.6 billion prescriptions dispensed in 1997.
Heavy managed care penetration has certainly contributed to the rise in prescription volume, as have an aging population, an increase in advertising and faster drug approval times. In recent years, managed care organizations have become more amenable to covering plan members' prescription drug costs because they believe it is ultimately less expensive therapy than more invasive procedures.
Chain community pharmacies, such as traditional chain drug stores, mass merchant chain pharmacies and supermarket chain pharmacies, will account for 61% of $102.5 billion in sales, dispensing more than 60% of the total amount of prescriptions.
NACDS predicted that the growth in prescriptions dispensed at community pharmacies will continue, and could reach a staggering 4 billion in the year 2005. For comparison, the number of retail prescriptions dispensed in 1992 was just over 2 billion. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.